Sabine D. Brookman-May/X
Apr 29, 2025, 20:04
Sabine D. Brookman-May Shares Sunrise1 Study Data on TAR200 in HR NMIBC
Sabine D. Brookman-May, Senior Vice President and Therapeutic Area Head Urologic Oncology at Aura Biosciences, shared on X:
“Impressive data presented by Joe Jacob from the Sunrise1 study with TAR200 in HR BCG unresponsive NMIBC CIS +/- papillary disease:
- 82.4% CR rate
- 25.8 months median DOR
- 52.9% of responses lasting more than 1 year “
In this post, Sabine D. Brookman-May spotlighted new data presented by Joe Jacob from the Sunrise1 study evaluating TAR200 in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The study reported a clinical complete response (CR) rate of 82.4%, a median duration of response (DOR) of 25.8 months, and over half of the responses lasting beyond one year—underscoring the therapeutic potential of TAR200 in a difficult-to-treat NMIBC population.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 29, 2025, 20:04
Apr 29, 2025, 19:13
Apr 29, 2025, 19:10
Apr 29, 2025, 18:33
Apr 29, 2025, 18:12
Apr 29, 2025, 18:10